Vietnam Drug Administration Rejects Changes In Price Cap Rules
This article was originally published in PharmAsia News
The Drug Administration of Vietnam told drug makers it has rejected their suggestions and will maintain current procedures controlling the prices of drugs. The companies had wanted the Health Ministry to drop its requirement that they present material invoices when they request price increases, and instead to base the price caps on marketing prices in the exporting country. The firms were told Vietnam intends to retain current policy of basing prices on cost, insurance and import transportation costs, the central factor drug makers want changed. Prices also are based on transportation and management costs, and on profit margins. (Click here for more
You may also be interested in...
GSK commits to investing behind OTC and oral health brands in India after offloading nutrition assets to Unilever.
The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.